Kestra Medical Technologies, Ltd.
NASDAQ:KMTSMedical - Instruments & Supplies
-$0.07 today
- Market cap
- $1.69B
- Beta
- 0.83
- P/E (TTM)
- -6.9
- EPS (TTM)
- -$2.74
Volume 0.44M
Average 0.33M
KMTS Other Income / Expenses
Net non-operating gains and losses, such as investment results, currency effects, and one-off items.
Kestra Medical Technologies, Ltd.NASDAQ: KMTS
Other Income / Expenses · Q3 FY2026 · quarter ended Jan 2026
Other income / expenses turns positive
Q3 FY2026 other income / expenses was $633K, compared with -$1.14M a year earlier. Trailing-twelve-month other income / expenses was -$75K.
Context
- Other income / expenses amounted to 12.2% of revenue in FY2025, down 20.3 pp from a year earlier.
- Other income / expenses grew in size in 2 of the last 3 fiscal years.
What to watch
Whether quarterly other income / expenses holds near $633K or moves back toward the trailing-twelve-month quarterly average of -$18.75K.
Sources:Income StatementText generated from reported figures; not investment advice.
Other Income / Expenses history
USD · from the income statement
- Latest · FY2025
- (7.3M) USD
- Year-over-year change
- +19.2%
| Period | Period end | Other Income / Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-04-30 | (7.3M) | +19.2% |
| FY2024 | 2024-04-30 | (9.03M) | -137.6% |
| FY2023 | 2023-04-30 | (3.8M) | — |
| FY2021 | 2021-04-30 | (1.21M) | — |
| FY2020 | 2020-04-30 | 0 | — |
Other Income / Expenses vs competitors
How KMTS compares with its peers on the latest reported figures
- KMTS's LTM Jan 2026 other income / expenses of -$75K is the 2nd highest of the 3 companies compared; the peer median is -$1.07M.
- Its year-over-year change of +98.8% is the highest of 3, against a peer median of -153.4%.
- Other income / expenses amounts to 0.1% of revenue for KMTS, versus a peer median of 2.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $545K | -86.6% | — | 0.1% | |
| LTM Jan 2026 | -$75K | +98.8% | — | 0.1% | |
| LTM Mar 2026 | -$2.68M | -220.2% | — | 4.5% | |
| Peer median (excluding KMTS) | -$1.07M | -153.4% | — | 2.3% | |
Competitors are the stored peer set for KMTS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2020 Apr 2020 | FY2021 Apr 2021 | FY2023 Apr 2023 | FY2024 Apr 2024 | FY2025 Apr 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 7.63M | 27.81M | 59.82M |
| Cost of Revenue | 0 | 0 | 18.28M | 27.45M | 35.61M |
| Gross Profit | 0 | 0 | (10.65M) | 362K | 24.21M |
| Gross Margin | — | — | -139.6% | 1.3% | 40.5% |
| Research & Development | 22.8M | 18.81M | 15.76M | 15.49M | 15.65M |
| Selling, General & Admin | 6.52M | 13.9M | 54.01M | 69.94M | 114.94M |
| Operating Expenses | 29.32M | 32.71M | 69.77M | 85.43M | 130.59M |
| Depreciation & Amortization | 478K | 420K | 4.86M | 11.56M | 7.97M |
| EBITDA | (28.84M) | (32.33M) | (73.74M) | (76.31M) | (97.98M) |
| EBITDA Margin | — | — | -966.4% | -274.3% | -163.8% |
| Operating Income | (29.32M) | (32.71M) | (80.42M) | (85.06M) | (106.38M) |
| Operating Margin | — | — | -1054.0% | -305.8% | -177.8% |
| Interest Income | 0 | 0 | 0 | 0 | 3.2M |
| Interest Expense | 0 | 1.17M | 5.63M | 6.23M | 7.73M |
| Other Income / Expenses | 0 | (1.21M) | (3.8M) | (9.03M) | (7.3M) |
| Income Before Tax | (29.32M) | (33.91M) | (84.22M) | (94.1M) | (113.68M) |
| Pre-Tax Margin | — | — | -1103.8% | -338.3% | -190.1% |
| Income Tax Expense | 148K | 187K | 15K | 24K | 135K |
| Net Income | (29.47M) | (34.1M) | (84.24M) | (94.12M) | (113.81M) |
| Net Margin | — | — | -1104.0% | -338.4% | -190.3% |
| EPS (Basic) | (0.59) | (0.69) | (1.75) | (2.04) | (5.13) |
| EPS (Diluted) | (0.59) | (0.69) | (1.75) | (2.04) | (5.13) |
| Weighted Avg Shares | 49.53M | 49.53M | 49.53M | 49.53M | 49.53M |
| Weighted Avg Shares (Diluted) | 49.53M | 49.53M | 49.53M | 49.53M | 49.53M |
Kestra Medical Technologies, Ltd.
NASDAQ:KMTS
Intrinsic Alpha fair value
Locked
Current Price
$28.29
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.